Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India
· Delayed Price · Currency is INR 2,745.00
-22.20 (-0.80%)
Jun 26, 2025, 3:30 PM IST
Dr. Lal PathLabs Revenue
In the fiscal year ending March 31, 2025, Dr. Lal PathLabs had annual revenue of 24.61B INR with 10.54% growth. Dr. Lal PathLabs had revenue of 6.03B in the quarter ending March 31, 2025, with 10.48% growth.
Revenue
24.61B
Revenue Growth
+10.54%
P/S Ratio
9.39
Revenue / Employee
4.94M
Employees
4,980
Market Cap
231.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 24.61B | 2.35B | 10.54% |
| Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
| Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
| Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
| Mar 31, 2021 | 15.81B | 2.51B | 18.86% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Dr. Lal PathLabs News
- 3 days ago - Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market - Business Upturn
- 3 days ago - Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests - Business Upturn
- 2 months ago - Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY - Business Upturn
- 8 months ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
- 8 months ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
- 8 months ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
- 8 months ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
- 8 months ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn